Corcept Therapeutics Faces Class Action Lawsuit Over Misleading Relacorilant Approval Claims

Corcept Therapeutics Faces Class Action Lawsuit Over Relacorilant Claims

Corcept Therapeutics Inc. stands at the center of a class action lawsuit filed by Robbins LLP, which represents investors who purchased the company’s stock between October 31, 2024, and December 30, 2025. The lawsuit stems from allegations that Corcept misled the market regarding the potential approval of its lead product candidate, relacorilant, which is designed to treat hypercortisolism, commonly referred to as Cushing's syndrome. During the specified period, the company asserted that its clinical trials offered "powerful support" for the New Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA). These optimistic claims suggested that no significant obstacles stood in the way of relacorilant's approval.

However, the lawsuit argues that Corcept did not fully disclose the challenges the company faced with its NDA submission. The FDA reportedly expressed concerns about the clinical evidence backing the drug’s efficacy, indicating a potential risk of outright rejection. Investors were not made aware of these critical discussions, which, according to the complaint, constitutes a significant breach of trust and transparency. On December 31, 2025, the company experienced a dramatic shift when it announced that the FDA issued a Complete Response Letter, stating the agency could not ascertain a favorable benefit-risk assessment for relacorilant without additional proof of its effectiveness. This revelation triggered a catastrophic drop in Corcept's stock price, representing a 50.4% decline, from $70.20 to $34.80 in just a single day.

For Corcept, this legal challenge poses serious implications not only in terms of potential financial liability but also regarding its reputation in the pharmaceutical industry. As a company specializing in cortisol modulation treatments, maintaining credibility and investor confidence is crucial. Misleading claims surrounding the efficacy of drug candidates can jeopardize future trials and product approvals, thereby affecting the company’s overall prospects in a highly competitive market. As the lawsuit unfolds, it will be essential for Corcept to address these allegations while working to reassure both investors and healthcare stakeholders about the integrity of its development processes.

Additionally, shareholders interested in participating in the class action or wish to lead the litigation on behalf of other investors can reach out to Robbins LLP for further information. The firm encourages all potential claimants to understand their choices regarding participation or remaining absent from the class. In a pharmaceutical landscape where trust is paramount, Corcept finds itself at a pivotal crossroads that may alter its trajectory in drug development and investor relations.